Top Page
LB Pharmaceuticals, Inc.
(NASDAQ:LBRX)
LB Pharmaceuticals, Inc. (LBRX) vs. SPDR S&P 500 ETF (SPY)
LB Pharmaceuticals, Inc. Business Overview & Revenue Model
LB Pharmaceuticals, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -81.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.91M | -63.01M | -1.45M | -12.19M |
| Net Income | -13.73M | -63.10M | -6.28M | -14.35M |
Balance Sheet | ||||
| Total Assets | 320.75M | 33.53M | 45.66M | 21.49M |
| Cash, Cash Equivalents and Short-Term Investments | 314.48M | 28.00M | 43.29M | 21.40M |
| Total Debt | 3.67M | 3.70M | 0.00 | 24.15M |
| Total Liabilities | 10.53M | 128.09M | 80.13M | 50.30M |
| Stockholders Equity | 310.22M | -94.55M | -34.47M | -28.81M |
Cash Flow | ||||
| Free Cash Flow | -17.12M | -53.82M | -12.12M | -2.73M |
| Operating Cash Flow | -17.11M | -53.05M | -12.09M | -2.73M |
| Investing Cash Flow | -39.85M | 23.23M | -28.01M | 123.00K |
| Financing Cash Flow | 303.73M | 38.31M | 33.68M | 22.96M |
LB Pharmaceuticals, Inc. Peers Comparison
LB Pharmaceuticals, Inc. Corporate Events
On March 13, 2026, LB Pharmaceuticals, Inc. announced that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the 2026 annual meeting of stockholders, with his term ending at that meeting. The company emphasized that his departure does not stem from any disagreement over operations or policies, and he will continue serving on the Board and its Nominating and Corporate Governance Committee until the meeting.
Following his resignation, Prensky is expected to continue providing consulting services under an amended Transition, Separation, and Consulting Agreement that became effective June 3, 2026. Under this amendment, he will receive previously agreed benefits and his outstanding unvested stock options will remain eligible to vest for the duration of the agreement, signaling a managed leadership transition designed to preserve continuity and retain his expertise for the company and its stakeholders.
The most recent analyst rating on (LBRX) stock is a Buy with a $78.00 price target. To see the full list of analyst forecasts on LB Pharmaceuticals, Inc. stock, see the LBRX Stock Forecast page.
On March 6, 2026, LB Pharmaceuticals appointed veteran neuroscience drug development executive Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director and member of the Nominating and Corporate Governance Committee, compensating him with cash retainers and stock options under its 2025 Equity Incentive Plan. Lenz, who has held senior R&D roles at Neumora Therapeutics, Amgen and Abbott, is expected to bolster oversight as the company advances its lead neuropsychiatric candidate LB-102 in late-stage development, potentially strengthening its scientific governance and credibility with investors and partners.
Separately, on March 4, 2026, the Board promoted Chief Business Officer Gad Soffer to Chief Operating and Business Officer, raising his annual base salary to $505,000 and maintaining his eligibility for a performance-based bonus. The expanded remit for Soffer is likely to concentrate operational and commercial execution under a single leader as LB Pharmaceuticals scales its late-stage pipeline activities, signaling a maturing organizational structure ahead of potential pivotal trials and future commercialization efforts.
The most recent analyst rating on (LBRX) stock is a Buy with a $78.00 price target. To see the full list of analyst forecasts on LB Pharmaceuticals, Inc. stock, see the LBRX Stock Forecast page.
On February 4, 2026, LB Pharmaceuticals entered into a securities purchase agreement with a group of institutional investors for a $100 million private placement comprising 3,306,571 shares of common stock and pre-funded warrants to purchase up to 1,417,107 additional shares, priced at $21.17 per share and $21.1699 per pre-funded warrant. The transaction, expected to close on or about February 6, 2026, is being conducted under a private placement exemption and accompanied by a registration rights agreement requiring the company to register the resale of the issued shares and warrant shares with the SEC. LB Pharmaceuticals plans to use the proceeds primarily to fund a Phase 2 clinical trial of LB-102 as an adjunctive treatment for major depressive disorder, targeted to begin in early 2027, alongside working capital and general corporate purposes. The planned multi-center, randomized, double-blind, placebo-controlled Phase 2 study will enroll about 380 patients with inadequate response to prior antidepressant therapy at roughly 50 sites across the U.S. and Europe, a design that underscores the company’s strategy to expand LB-102’s potential use beyond schizophrenia into the large and underserved MDD market, which could materially influence its future growth trajectory if clinical results are favorable.
The most recent analyst rating on (LBRX) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on LB Pharmaceuticals, Inc. stock, see the LBRX Stock Forecast page.